Pharmaceutical - Anti-virals, Licensing


Current filters:


Popular Filters

1 to 25 of 29 results

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1


ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine


Privately-held California, USA-based specialty vaccine firm PaxVax has entered into a research and development…


Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products


Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Roche in up to $422.5 million deal with Inovio Pharma


Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


BioLineRx collaborates with Chinese firm on hep C drug BL-8030


Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon


US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Roche teams up with Ascletis on hep C treatments for China


Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Merck & Co in-licenses portfolio targeting HCMV from AiCuris for up to $570 million


US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide licensing agreement with…

AiCurisAnti-viralsletermovirLicensingMerck & CoPharmaceutical

Novartis restructures deal with Idenix Pharmaceuticals


USA-based Idenix Pharmaceuticals (Nasdaq: IDIX) says that Swiss drug major Novartis (NOVN: VX) has restructured…

Anti-viralsIdenix PharmaceuticalsLicensingNovartisPharmaceuticaltelbivudine

Merck & Co in-licenses Chimerix antiviral; Fiocruz to make ARVs in Africa


USA-based Chimerix, a venture-funded biotech focused on developing novel oral antivirals, has announced…

Anti-viralsChimerixCMX001CMX157FiocruzGlobalLicensingMarkets & MarketingMerck & CoPharmaceuticalRest of the World

Research news: dolutegravir; TD-1211; and synaptic modulators


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Teva gets rights to BioAlliance's Sitavig in Israel


French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has signed an exclusive license agreement for…

Anti-viralsBioAlliance PharmaLicensingPharmaceuticalRest of the WorldSitavigTeva Pharmaceutical Industries

Bristol-Myers expands hepatitis C accord with Medivir and Janssen


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Enanta Pharma in $440 HCV licensing deal with Novartis


USA-based discovery and development company Enanta Pharmaceuticals yesterday signed an exclusive collaboration…

Anti-viralsEnanta PharmaceuticalsLicensingNovartisPharmaceutical

BioLineRx in-licenses BL-8020, an oral hepatitis C treatment


Israeli biopharma company BioLineRx (Nasdaq: BLRX) says it has signed a worldwide, exclusive license…


Dendreon cashes in Victrelis royalty


US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

1 to 25 of 29 results

Back to top